Babies with jaundice that has not subsided by the end of the first month of life are at risk of brain entry, or bilirubin encephalopathy, which is one of the complications of jaundice, but is not absolute.
Bilirubin encephalopathy is the most common complication of neonatal hyperbilirubinemia, accounting for 4.8% of all neonatal hyperbilirubinemic infants, and is manifested by elevated serum unconjugated total bilirubin. Jaundice does not subside after the first month of life, and if the jaundice is high and no treatment is given, bilirubin encephalopathy, commonly known as jaundice in the brain, may develop.
However, not all newborns whose jaundice does not subside after the first month of life will necessarily be cerebral, and some patients can be cured after standardized treatment, such as blue light irradiation and jaundice-reducing drugs. If the child’s jaundice level is high and progresses quickly, if necessary, blood exchange therapy should be taken to treat.
It is recommended that when the baby’s jaundice has not receded after a full month, the family should keep a good mood and actively cooperate with the doctor to carry out standardized treatment, so that the jaundice value of the child can be reduced.